S&P 500 slips on report Fed’s Waller leading race to replace Powell; tech shines
Investing.com - BeOne Medicines DRC (NASDAQ: ONC) reported second quarter EPS of $0.17, $0.04 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $1.32B versus the consensus estimate of $1.24B.
Guidance
BeOne Medicines DRC sees Q3 2025 revenue of $5.00B-$5.30B versus the analyst consensus of $5.13B.
BeOne Medicines DRC’s stock price closed at $307.23. It is up 32.43% in the last 3 months and up 73.84% in the last 12 months.
BeOne Medicines DRC saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See BeOne Medicines DRC’s stock price’s past reactions to earnings here.
According to InvestingPro, BeOne Medicines DRC’s Financial Health score is "great performance".
Check out BeOne Medicines DRC’s recent earnings performance, and BeOne Medicines DRC’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar